Aprecia Pharmaceuticals Co. entered an up to $30 million debt financing agreement with Hercules Capital Inc.
Aslan Pharmaceuticals Pte Ltd. completed a $23 million series D financing.
Biogeneration Management III BV made the first close of its new venture capital fund, Biogeneration Capital Fund III C.V., with a target fund size of $55.4 million.
Cstone Pharmaceuticals Co. Ltd. closed its series A round of $150 million.
Ignyta Inc. secured a $42 million term loan facility from Silicon Valley Bank and Oxford Finance.
Intercept Pharmaceuticals Inc. closed its underwritten public offering of $460 million of 3.25 percent convertible senior notes due 2023.
Kitov Pharmaceuticals Holdings Ltd. closed its public offering for gross proceeds of about $12 million.
Sernova Corp. completed a nonbrokered private placement of $4.2 million.
Syros Pharmaceuticals Inc. closed its IPO of 4.6 million shares at $12.50 each.
Tesaro Inc. priced an underwritten public offering for gross proceeds for about $376.7 million.
Arbor Pharmaceuticals LLC completed its tender offer to purchase all issued and outstanding shares of common stock of Xenoport Inc. for $7.03 per share in cash, for a total $467 million.
Bristol-Myers Squibb Co. is acquiring Cormorant Pharmaceuticals AB, which is advancing Humax-IL8, in breast cancer and other solid tumors.
Evotec AG said it entered a nonexclusive license agreement with the Broad Institute of MIT and Harvard University for the use of CRISPR-Cas9 gene-editing technology.
Helsinn Healthcare SA and Vifor Pharma signed an exclusive promotion and distribution agreement for Aloxi, a therapeutic used to help prevent symptoms of chemotherapy-induced nausea and vomiting, in Spain.
HTG Molecular Diagnostics Inc. and Firalis SA are developing a next-generation sequencing-based theranostic tool to identify likely nonresponders from responders to anti-TNF-alpha therapy for rheumatoid arthritis.
Leo Pharma A/S is paying $115 million up front to Astrazeneca plc to take on development of tralokinumab, an interleukin-13 inhibitor, in atopic dermatitis, and the IL-17 receptor inhibitor brodalumab in plaque psoriasis.
Medivation Inc. has entered into confidentiality agreements with a number of potential acquirers.
Orasure Technologies Inc. and Abbvie Inc. mutually agreed to an early termination of an agreement under which the companies have been co-promoting Orasure's Oraquick hepatitis C virus rapid antibody test in the U.S.
Sprint Bioscience AB and the Center for Hematology and Regenerative Medicine at the Karolinska Institute will evaluate Sprint drug candidates for the treatment of acute myeloid leukemia.
Syndax Pharmaceuticals Inc. entered an exclusive worldwide license agreement with UCB SA for UCB6352, an IND-ready anti-CSF-1R monoclonal antibody.
Takeda Pharmaceutical Co. Ltd. and Altos Therapeutics LLC agreed to further develop Altos's sole compound, the oral dopamine D2/D3 receptor antagonist ATC-1906.
Tigenix NV signed a deal with Takeda Pharmaceutical Co. Ltd. for its allogeneic cell therapy for Crohn's disease, Cx601.
Vertex Pharmaceuticals Inc. and Moderna Therapeutics Inc. signed an exclusive research collaboration and licensing agreement aimed at the discovery and development of messenger ribonucleic acid therapeutics for the treatment of cystic fibrosis.
. . . AND MORE
Abbvie Inc. and Biogen Inc. said the EC granted marketing authorization for Zinbryta (daclizumab) for the treatment of adult patients with relapsing forms of multiple sclerosis.
Abbvie Inc. said the FDA approved Humira (adalimumab) for the treatment of non-infectious intermediate, posterior and panuveitis.
Araim Pharmaceuticals Inc. said the FDA granted orphan drug designation for its lead product candidate, innate repair receptor activator ARA 290, for the treatment of sarcoidosis.
Arena Pharmaceuticals Inc. is reducing its U.S. workforce by about 100 employees, or 73 percent, primarily in areas of research, manufacturing and G&A as it seeks to reduce its annualized cash expenditures.
Bind Therapeutics Inc. filed a motion for court approval of a stalking horse asset purchase agreement bid from Pfizer Inc. for the purchase of the majority of its assets.
Insys Therapeutics Inc. has won FDA approval for Syndros, an orally administered liquid formulation of cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol.
Kyowa Hakko Kirin Co. Ltd. said Lumicef (brodalumab), a subcutaneously injected interleukin-17A antibody, was approved in Japan.
Pernix Therapeutics Holdings Inc. reduced its full-time workforce by about 23 percent as part of a reorganization plan, which includes cutting 54 sales positions, primarily from the neurology sales team.
Valneva SE has generated a highly purified inactivated vaccine candidate against the Zika virus, developed using the same manufacturing platform as its approved Japanese encephalitis vaccine.